Key Takeaways Galafold raked in $371.5M in the first nine months of 2025, accounting for over 80% of FOLD's product sales.Galafold benefits from broad global approvals and U.S. patent protection extending through 2038.FOLD's Pombiliti Opfolda delivered $77.5M sales in the first nine months of 2025, up 61% Y/Y.Amicus Therapeutics (FOLD) has made solid progress with its lead marketed product, Galafold (migalastat), which generates the majority of the company’s revenues.Galafold is approved for treating Fabry ...

Key Takeaways FOLD touched a 52-week high as shares rally 87.6% in six months, beating the industry, sector and S&P 500.Galafold is the key revenue driver, generating $371.5M in the first nine months of 2025, up 12% Y/Y.Pombiliti Opfolda sales reached $77.5M in the first nine months of 2025, reflecting 61.5% y/y growth.Shares of Amicus Therapeutics (FOLD) touched a 52-week high of $11.14 on Dec. 15. The stock is currently trading at $10.88.Shares of Amicus have surged 87.6% in the past six months compared w ...

Key Takeaways FOLD's Galafold delivered $371.5M in the first nine months of 2025, up 12% year over year.Patent settlement with Teva blocks Galafold generics in the United States until January 2037.FOLD's Pombiliti Opfolda earned $77.5M in nine-month 2025 sales, rising 61.5% year over year.Amicus Therapeutics (FOLD) has been making meaningful progress with its lead product, Galafold (migalastat), which has been driving the majority of the company’s revenues. The drug has remained a key top-line driver for Am ...

Core Insights - Amicus Therapeutics' lead product, Galafold, is the primary revenue driver for the company, being the first oral precision medicine approved for Fabry disease treatment [1][2] - Galafold sales reached $233.1 million in the first half of 2025, reflecting an 11% year-over-year increase, with a projected CAGR of 11.7% over the next three years [2][9] - The company has secured strong patent protection for Galafold in the U.S. until 2038, following a licensing agreement with Teva Pharmaceuticals that prevents generic competition until January 2037 [3][4][9] Product Performance - Galafold has shown consistent sales growth since its launch, with label expansions and approvals in new regions contributing to its revenue increase [2][3] - The combination therapy Pombiliti + Opfolda for late-onset Pompe disease generated $46.8 million in sales during the first half of 2025, marking a 74% year-over-year increase [5] Market Dynamics - Amicus is heavily reliant on Galafold for revenue, which poses risks if regulatory challenges arise [6] - The company faces significant competition from established players in the lysosomal storage disorder market, including Sanofi and Takeda Pharmaceuticals, which market products for Fabry and Pompe diseases [7][8]